RepliCart (Prod 9444)






About RepliCart (Prod 9444)

Mesoblast announced this week that the company received Australian institutional ethics committee approval to begin a clinical study evaluating the use of its adult stem cell product, RepliCart, for the prevention of OA in patients who have had ACL repair. This will be the first human stem cell study for that indication.

Request Product Information

Disclaimer:

OrthopaedicLIST.com is a list of products and services. Every effort is made to keep this listing as accurate and current as possible. Companies and individuals are encouraged to notify us of errors and omissions. We will respond to such messages of correction in a timely fashion, as our workload permits.

We are non-judgmental of products listed. We are not in the business of evaluating products. We have not evaluated these products. We make no representations as to the quality, effectiveness, suitability or appropriateness of any of the products listed.

As an important component of the service function of OrthopaedicLIST.com, some products continue to be listed that are no longer manufactured and may not be available. We will identify them as such when possible. This allows users to find special instruments and/or components for removal, modification, and/or revision of those products.